ArticleTargeted oncology2026
Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAdvanced ovarian cancer carries a poor prognosis despite standard surgery and chemotherapy. Although poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib and niraparib, have recently become standard maintenance therapy, they can cause hematologic and non-hematologic toxicities, and data on their safety in older Japanese patients are limited.
objectiveWe aimed to evaluate the incidence of clinically significant severe adverse events (SAEs), treatment interruptions, and discontinuation of PARP inhibitor maintenance therapy according to age in Japanese patients with ovarian cancer.
methodsThis retrospective cohort study used data from the Japanese Diagnosis Procedure Combination database. Patients diagnosed with ovarian cancer who received treatment with PARP inhibitors approved in Japan (olaparib, olaparib plus bevacizumab, or niraparib) after surgery and chemotherapy were included. Clinically significant SAEs were identified using diagnostic and billing codes rather than laboratory-confirmed Common Terminology Criteria for Adverse Events (CTCAE) grading. Outcomes were assessed across two age groups (< 65 vs. ≥ 65 years) using inverse probability weighting to account for baseline differences.
resultsAfter adjustment, the baseline characteristics were balanced among the 1083 patients included in this study (olaparib, 315; olaparib plus bevacizumab, 343; niraparib, 425). In the olaparib group, patients aged ≥ 65 years showed a higher incidence of clinically significant neutropenia compared with those aged < 65 years (incidence rate ratio 7.47; 95% confidence interval 2.37-23.5). In contrast, no significant age-related differences were observed in the incidence of other clinically significant SAEs. Rates of hospitalization, treatment interruption, and treatment discontinuation were generally comparable between the age groups across all regimens.
conclusionOverall, PARP inhibitor maintenance therapy appeared to be generally tolerated in older patients in this real-world cohort. However, older individuals who received olaparib monotherapy experienced a significantly higher incidence of clinically significant neutropenia, indicating the need for careful monitoring and individualized dose management in this subgroup.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.